0001520138-23-000457.txt : 20231025 0001520138-23-000457.hdr.sgml : 20231025 20231025130410 ACCESSION NUMBER: 0001520138-23-000457 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20231025 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231025 DATE AS OF CHANGE: 20231025 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOVIE INC. CENTRAL INDEX KEY: 0001580149 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 462510769 STATE OF INCORPORATION: NV FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39015 FILM NUMBER: 231344839 BUSINESS ADDRESS: STREET 1: 680 W NYE LANE STREET 2: SUITE 201 CITY: CARSON CITY STATE: NV ZIP: 89703 BUSINESS PHONE: 775-888-3162 MAIL ADDRESS: STREET 1: 680 W NYE LANE STREET 2: SUITE 201 CITY: CARSON CITY STATE: NV ZIP: 89703 FORMER COMPANY: FORMER CONFORMED NAME: NANOANTIBIOTICS, INC. DATE OF NAME CHANGE: 20130625 8-K 1 bivi-20231025_8k.htm CURRENT REPORT
false 0001580149 0001580149 2023-10-25 2023-10-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): October 25, 2023

 

BioVie Inc.
(Exact Name of Registrant as Specified in Its Charter)

 

Nevada 001-39015 46-2510769
(State or Other Jurisdiction
of Incorporation)		 (Commission File Number) (I.R.S. Employer Identification No.)
     

 

680 W Nye Lane Suite 201

Carson City, NV

   89703
(Address of Principal Executive Offices)   (Zip Code)
     

(775) 888-3162
(Registrant’s Telephone Number, Including Area Code)

 

(Former Name or Former Address, if Changed Since Last Report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which
registered
Class A Common Stock, par value $0.0001 per share BIVI The Nasdaq Stock Market, LLC

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

  ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 8.01 Other Events.

 

On October 25, 2023, BioVie Inc. (the “Company”) issued a press release announcing the presentation of blinded data from the Company’s Phase 3 clinical trial of NE3107 in the treatment of mild to moderate Alzheimer’s Disease (AD) at the 16th Clinical Trials on Alzheimer’s Disease (CTAD) in Boston, MA.

 

The Company is filing a copy of the press release, which is attached hereto as Exhibit 99.1 and incorporated herein by reference.

 

Forward-Looking Statements

 

This Current Report on Form 8-K contains forward-looking statements, which may be identified by words such as “expect,” “look forward to,” “anticipate” “intend,” “plan,” “believe,” “seek,” “estimate,” “will,” “project” or words of similar meaning. In this report, forward-looking statements include, but are not limited to, the potential impact of NE3107 on cognition and function among study participants and the timeline for announcing unblinded, topline data from the NE3107 trial. Although BioVie Inc. believes such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Actual results may vary materially from those expressed or implied by the statements herein due to the risk that unblinded data is not consistent with blinded data, the Company’s ability to successfully raise sufficient capital on reasonable terms or at all, available cash on hand and contractual and statutory limitations that could impair the Company’s ability to pay future dividends, the Company’s ability to complete the Company’s pre-clinical or clinical studies and to obtain approval for the Company’s product candidates, the Company’s ability to successfully defend potential future litigation, changes in local or national economic conditions as well as various additional risks, many of which are now unknown and generally out of the Company’s control, and which are detailed from time to time in reports filed by the Company with the Securities and Exchange Commission, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. BioVie Inc. does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law.

 

Item 9.01 Financial Statements and Exhibits
   

 

(d) Exhibits.

 EXHIBIT INDEX

 

Exhibit No.   Description
99.1   Press Release, dated October 25, 2023.
104  

Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101)

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: October 25, 2023

 

  BIOVIE INC.
     
  By: /s/ Joanne Wendy Kim
  Name:   Joanne Wendy Kim
  Title: Chief Financial Officer

  

 

 EX-99.1 2 bivi-20231025_8kex99z1.htm EXHIBIT 99.1

FOR RELEASE OCTOBER 25, 2023 AT 12:20PM ET

 

Blinded Data Presented at CTAD Suggest that NE3107 is Biologically Active and May Have Impact on Cognitive, Biomarker, and Imaging Endpoints Among
Mild to Moderate Alzheimer’s Disease Patients

 

·Statistically significant population changes from baseline were observed for all primary and secondary cognitive and functional assessments measured: ADAS-Cog12, ADCS-CGIC, MMSE, CDR, CDR-SB, ADCOMS, and ADL.[1]
·An apparent significant reduction in amyloid burden from baseline was observed in the population.
oA significant change from baseline was observed in the Amyloid β 42/40 ratio and Amyloid Probability Score as shown by the PrecivityAD® tests from C2N Diagnostics.
oIncreased FDG-PET SUVRs were observed in 10 out of 21 patients in a brain imaging sub-study, which is suggestive of reduced amyloid burden.
·Statistically significant increases in insulin and beta cell function were observed without any hypoglycemia, which suggests target engagement and lends support for a previously identified potential mechanism of action for NE3107.
·The Company expects to announce unblinded, topline data from this trial in late November or early December.

 

Carson City NV, October 25, – BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders,  announced that blinded data on cognitive, biomarker and imaging findings from the recently completed Phase 3 clinical trial (NCT04669028) of NE3107 in the treatment of mild to moderate Alzheimer’s Disease (AD) were presented today as an oral presentation at the 16th Clinical Trials on Alzheimer’s Disease (CTAD) in Boston, MA,

 

The presentation, Clinical Outcomes from a Phase 3, Randomized, Placebo-Controlled Trial of NE3107 in Subjects with Mild to Moderate Probable Alzheimer’s Disease, detailed a cross sectional analysis of blinded data from BioVie’s Phase 3 study and discussed participants whose data were available for analysis as of October 18, 2023 (n=322). These preliminary analyses will be updated once the complete and final dataset becomes available and when the study database is locked, unblinded and analyzed in full.

 

The blinded data presented suggest that NE3107 is a biologically active compound exerting potential effects as observed by biomarker, imaging, cognitive and functional assessments. Population changes from baseline were observed, with some patients demonstrating an improvement after 30 weeks of treatment with the double blinded oral study drug (NE3107 or matched placebo) as compared to baseline, while many were also observed to have worsened, which is consistent with the natural progression of the disease (Figure 1).

 

[1]ADAS-Cog12: Alzheimer’s Disease Assessment Scale-Cognitive; ADCS-CGIC: Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change; MMSE: Mini-Mental State Examination; CDR: Clinical Dementia Rating; CDR-SB: Clinical Dementia Rating-Sum of Boxes; ADCOMS: Alzheimer's disease composite score; ADCS-ADL: Alzheimer’s Disease Cooperative Study-Activities of Daily Living
 
 

Since study participants diagnosed with dementia would typically be expected to worsen or experience no change as a function of time-related disease progression without active treatment, the observed“scattering” pattern in the blinded data suggests that NE3107 may have an impact on cognition and function among study participants, and the magnitude of cognitive and functional improvements observed is not consistent with typical placebo response observed in historical clinical studies in AD. While patients were randomized 1:1 to NE3107 vs. placebo, a plurality of subjects showed evidence of improvement and may have demonstrated effects unrelated to the administration of the study drug (NE3101 or placebo).

 

Figure 1. Cognitive and functional changes from baseline

 

Consistent directionality and significant correlations (p<0.0001) were observed among differing assessment scales, which underscores the uniformity of change on different measures of the patients’ condition over the course of the 30-week study.

Spearman r CGIC MMSE CDR CDR SB ADCOMS ADL
ADAS-Cog12 +0.24 -0.46 +0.23 +0.23 +0.51 -0.40
CGIC   -0.50     +0.46 -0.40
MMSE     -0.38 -0.42 -0.63 +0.34
CDR-SB         +0.79 -0.21
ADCOMS           -0.23

All correlations were significant at p<0.0001

 

An apparent significant reduction in the population’s amyloid burden was observed (Figure 2), as measured by C2N Diagnostics’ PrecivityAD® test. The PrecivityAD® blood test is a FDA-validated assay that relies on the Aβ42/Aβ40 ratio and other factors to predict the Amyloid Probability Score, which identifies whether a patient is likely to have the presence or absence of amyloid plaques in the brain and is highly correlated to amyloid levels measured by PET.

 

[2]Doecke et al. Neurology Apr 2020, 94 (15) e1580-e1591
[3]Pérez-Grijalba et al. J Prev Alzheimers Dis. 2019;6(1):34-41

 -2-

 

A low ratio of Aβ42/Aβ40 has been shown to be a reliable predictor of the amyloid-PET status[2] and disease progression.[3] The scattering pattern in the blinded data and the large number of patients experiencing an increase in this ratio compared to baseline may be suggestive of NE3107’s effect. These data showed that 36.5% of patients with positive PrecivityAD® scores at baseline reverted to having negative results after 30 weeks, whereas 14.4% of patients with negative scores at baseline converted to positive results over this timeframe.

 

Figure 2. Changes in Amyloid burden

 

Statistically significant increases in insulin and beta cell function (HOMA2-%B +13.5%, p<0.0001) and decreased insulin sensitivity (HOMA2-%S -21.2%, p<0.0001) were observed in the blinded data and may further confirm NE3107’s potential ability to improve insulin signaling observed in previous trials. No cases of hypoglycemia were reported in the study.

 

In a small doubled blinded imaging sub-study, increased FDG-PET Standard Uptake Value Ratios (SUVRs) were observed in the blinded data in 10 out of 21 patients. FDG-PET is a recognized biomarker for neurodegeneration, and lower SUVRs are associated with disease progression.[4]

 

The rate and nature of adverse events in the blinded data appear consistent with prior clinical studies of NE3107.

“The blinded data presented at CTAD show encouraging changes from baseline that would not typically be seen without a treatment effect, which provides us with confidence that NE3107 may show a clear benefit over placebo when the data from this trial is unblinded in the coming weeks,” commented Joseph Palumbo, BioVie’s Chief Medical Officer. “We believe NE3107 has the potential become to effective multi-mechanistic treatment for Alzheimer's that is safe and can be orally administered.”

 

The last patient came in for the last treatment visit in late September 2023, and the Company is currently resolving outstanding database queries and preparing for database freeze and data unblinding. The Company expects to announce unblinded, topline data from this trial in the November/December timeframe.

 

[4]Marcus et al. Clin Nucl Med. 2014 Oct; 39(10): e413–e426.

 -3-

 


About the NCT04669028 Trial

 

The NCT04669028 trial is a Phase 3, double-blind, randomized, placebo-controlled, parallel group, multicenter study of NE3107 in patients who have mild- to moderate-AD and CDR 1-2 and MMSE 14-24. The study has co-primary endpoints looking at cognition using the Alzheimer’s Disease Assessment Scale-Cognitive Scale (ADAS-Cog 12) and function using the Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC). Patients went through two weeks each of 5 mg and 10 mg BID dose titration followed by 26 weeks of 20 mg twice daily vs. placebo, randomized 1:1.

 

Prior clinical results indicate that NE3107 may be capable of reducing inflammation in a manner that was in some cases significantly correlated with observed improvements in cognition. Specifically, in July 2023, the Company presented a poster detailing the epigenetic basis for how NE3107 may have the potential to regulate methylation of specific genes in a manner that significantly correlated with observed cognitive and biomarker improvements at the Alzheimer’s Associate’s International Conference (AAIC) held in Amsterdam from July 16 through July 20, 2023. The poster presentation titled Treatment-Induced Epigenetic Modifications in MCI and Probable Alzheimer’s (Reading C, et al.), showed how patients with clinical dementia treated with NE3107 for three months saw significant reductions in the level of DNA methylation, and that such reductions were, in some cases, significantly correlated with observed improvements in various cognitive measures (e.g., ADAS-Cog11, CDR, ADCOMS, QDRS) and biomarkers(including TNFα, CSF p-Tau/Aβ 42 , precuneus glutathione). NE3107’s potential ability to reduce inflammation and insulin resistance suggests that it may be of benefit to both Aβ+ and Aβ− patients as well as APOE ε4+ and APOE ε4− patients.

 

About NE3107

 

NE3107 is an oral, small molecule, blood-brain permeable anti-inflammatory insulin sensitizer that binds extracellular signal-regulated kinase. BioVie’s Phase 3 trial is the largest study to date to evaluate the safety and efficacy of NE3107 in patients with AD. NE3107 is the only anti-inflammatory agent currently in phase 3 development for AD. Consistent with the proposed anti-inflammatory and insulin-sensitizing properties of NE3107, this phase 3 study was designed to confirm the efficacy and safety of NE3107 treatment in patients with probable AD.

 

 -4-

 

About BioVie  

 

BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company’s drug candidate NE3107 inhibits inflammatory activation of ERK and NFkB (e.g., TNF signaling) that leads to neuroinflammation and insulin resistance, but not their homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both are drivers of Alzheimer’s and Parkinson’s diseases. The Company is conducting a Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease (NCT04669028). Results of a Phase 2 investigator-initiated trial (NCT05227820) showing NE3107-treated patients experienced improved cognition and biomarker levels were presented at the Clinical Trial in Alzheimer’s Disease (CTAD) annual conference in December 2022. An estimated six million Americans suffer from Alzheimer’s. A Phase 2 study of NE3107 in Parkinson’s disease (NCT05083260) has completed, and data presented at the International Conference on Alzheimer's and Parkinson's Disease and Related Neurological Disorders conference in Gothenburg, Sweden in March 2023 showed significant improvements in “morning on” symptoms and clinically meaningful improvement in motor control in patients treated with a combination of NE3107 and levodopa vs. patients treated with levodopa alone, and no drug-related adverse events. In liver disease, the Company’s Orphan drug candidate BIV201 (continuous infusion terlipressin), with FDA Fast Track status, is being evaluated and discussed with guidance received from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the treatment of ascites due to chronic liver cirrhosis. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis. For more information, visit http://www.bioviepharma.com/. 

 

 

Forward-Looking Statements

 

This press release contains forward-looking statements, which may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. Although BioVie Inc. believes such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Actual results may vary materially from those expressed or implied by the statements herein due to the risk that unblinded data is not consistent with blinded data, the Company's ability to successfully raise sufficient capital on reasonable terms or at all, available cash on hand and contractual and statutory limitations that could impair our ability to pay future dividends, our ability to complete our pre-clinical or clinical studies and to obtain approval for our product candidates, our ability to successfully defend potential future litigation, changes in local or national economic conditions as well as various additional risks, many of which are now unknown and generally out of the Company's control, and which are detailed from time to time in reports filed by the Company with the SEC, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. BioVie Inc. does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law.

 

For Investor Relations Inquiries: 

   
Contact: 
Bruce Mackle 
Managing Director 
LifeSci Advisors, LLC 
bmackle@lifesciadvisors.com 		  
   
   

For Media Inquires

Melyssa Weible

Managing Partner, Elixir Health Public Relations 

Ph: +1 201-723-5705

mweible@elixirhealthpr.com

 

 -5-

 EX-101.PRE 3 bivi-20231025_pre.xml XBRL PRESENTATION FILE EX-101.SCH 4 bivi-20231025.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 bivi-20231025_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] GRAPHIC 6 image_003.jpg GRAPHIC begin 644 image_003.jpg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image_004.jpg GRAPHIC begin 644 image_004.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Oct. 25, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Oct. 25, 2023
Entity File Number 001-39015
Entity Registrant Name BioVie Inc.
Entity Central Index Key 0001580149
Entity Tax Identification Number 46-2510769
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 680 W Nye Lane
Entity Address, Address Line Two Suite 201
Entity Address, City or Town Carson City
Entity Address, State or Province NV
Entity Address, Postal Zip Code 89703
City Area Code (775)
Local Phone Number 888-3162
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Class A Common Stock, par value $0.0001 per share
Trading Symbol BIVI
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 9 bivi-20231025_8k_htm.xml IDEA: XBRL DOCUMENT 0001580149 2023-10-25 2023-10-25 iso4217:USD shares iso4217:USD shares false 0001580149 8-K 2023-10-25 BioVie Inc. NV 001-39015 46-2510769 680 W Nye Lane Suite 201 Carson City NV 89703 (775) 888-3162 Class A Common Stock, par value $0.0001 per share BIVI NASDAQ false false false false false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://bioviepharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports bivi-20231025.xsd bivi-20231025_8k.htm bivi-20231025_lab.xml bivi-20231025_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "bivi-20231025_8k.htm": { "nsprefix": "bivi", "nsuri": "http://bioviepharma.com/20231025", "dts": { "schema": { "local": [ "bivi-20231025.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "inline": { "local": [ "bivi-20231025_8k.htm" ] }, "labelLink": { "local": [ "bivi-20231025_lab.xml" ] }, "presentationLink": { "local": [ "bivi-20231025_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://bioviepharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-10-25", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20231025_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-10-25", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20231025_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001520138-23-000457-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001520138-23-000457-xbrl.zip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end